Primary prevention and management of variceal bleeding: Review of Historical Evidence by Suliman, MOM
 
© Sudan JMS Vol. 3, No. 1, Mar 2008                                          49 
 
 





 Prevention and control of active bleeding caused by portal hypertension is still a 
challenge. Surgery used to be the only option in the earlier days, but now many 
options exist. Choice of the correct mode of treatment is important and is 
determined by many factors dictated by the condition of each patient and the 
available experience.  
Methods: 
 Publications written on the primary prevention and the management of acute 
bleeding are selected by Internet search. The strength of evidence of each publication is determined using a 
defined classification method. The advice given is based on the available evidence. 
Results: 
 Seventy-two publications were retrieved. The level of evidence for each publication is given in the reference 
section.  
Conclusion: 
 Surgery should not be done for primary prophylaxis. For the control of acute bleeding surgery is preferred 
for Childs-Pough class A and B. For class C the procedure of choice is TIPS.   
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hipple popularized a surgical 
solution to the problem of bleeding 
in portal hypertension in the 
1940s1. Since that time many surgical 
operations were developed in the quest for 
better results. No perfect operation was ever 
found. For this reason, other types of 
solutions came successively into play. 
Pharmacotherapy, endoscopic therapy, liver 
transplantation and lastly TIPS have all joined 
the armamentarium. All these treatment 
modalities are now used in the developed 
world, each with a different indication. The 
deficient infrastructure of the hospitals and 
lack of expertise shorten the list of 
alternatives in the developing world.  
Objectives: 
     The objectives of this review are: 
      1- To determine the shareholding of each 
treatment modality in the primary prevention 
and management of bleeding caused by portal 
hypertension. 
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2- To determine the need for surgery in the 
primary prevention and management of 
acute bleeding that is supported by 
evidence. 
Methods: 
   - The Internet was searched using the 
words: portal hypertension, treatment, 
surgery, operations, management, meta-
analysis, variceal bleeding, in different 
combinations. 
 - The search was done through the following 
search engines: 
  a) PubMed through HINARI (a WHO site 
with free access to most journals). This is 
searched by two means: 
1. The general PubMed searching bar. 
2. MeSh Database by MeSh terms. 
   b) The Cochrane Review site. 
   c) Google general searching bar. 
   d) Yahoo general searching bar. 
       Selected references from publications 
found by the primary search were retrieved by 
a secondary search using the above search 
strategy.  
Selection of papers: 
  - No time limit. 
  - Language: English only.  
W
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 - All types of research are included e.g. meta-
analysis, controlled trials, case studies, 
narrative reviews, etc.. 
 - Publications with full text or abstract 
available on the Internet are included. 
 - Some publications thought to be important 
for the review could not be retrieved. Some 
because they are written in a language other 
than English, with no English abstract, but 
others simply could not be found by the 
search methods applied. 
Strength of evidence: 
   The strength of evidence is divided into 
levels taking into consideration the available 
grading systems2,3,4.  
 Level 1: Meta-analysis of randomized trials.  
 Level 2: Randomized trials.  
 Level 3: Non randomized, controlled trials, 
well written qualitative reviews dealing with 
mixed trials,   case control studies. 
Comparative studies. 
 Level 4: Case studies.  
 Level 5: Expert opinion. These include 
personal contacts of experts, editorials and 
published comments in respected journals. 
Results:    
Sixty nine publications are included in this 
review.   
Introduction:   
     The incidence of gastroesophageal varices 
in patients with a history of schistosomiasis is 
not known, but in cirrhotic patients is around 
50%5. Bleeding from these varices is caused 
by the increase in portal venous pressure that 
is directly related to the degree of outflow 
resistance and the portal venous inflow6.  
   The risk factors that point to the possibility 
of variceal bleeding are: 
- Portal pressure above 12 mm Hg. 
- Varix size and location. The potential 
bleeders are mainly those of the oesophagus 
and the stomach, other locations 
(retroperitoneal, anal canal etc.) rarely bleed. 
- Variceal appearance on endoscopy (red 
sign). 
- Degree of liver damage; Child-Pugh class C 
cirrhosis. 
- Presence of tense ascites. 
     The roadmap of treatment: 
   Surgical treatment was tried since 1929 in 
Mayo Clinic7 and in 1939 Crafoord and 
Frenckner wrote about a new treatment for 
varicose veins of the oesophagus8. During the 
1930s other treatment options were restricted 
to balloon tamponade and rigid endoscopic 
sclerotherapy5. 
     In 1945 Whipple introduced the total 
portacaval shunt operation1 which proved to 
be more acceptable and gave a better control 
of the bleeding problem which was the main 
reason for treatment. Since then surgery 
becomes the major treatment option for 
bleeding portal hypertension. All through that 
decade, the 1950s and until the middle of 
1960s these operations continued to be used 
inspite of the high incidence of 
encephalopathy9. The perfect control of 
bleeding followed by severe encephalopathy 
made the total shunt operations 
unacceptable10 and another operation had to 
be found.  
    In 1967 Warren introduced the distal 
splenorenal shunt (DSRS) which is a selective 
shunt11. This operation showed great 
success12 that the result of any other mode of 
treatment which was introduced thereafter had 
to be compared to it13.  Although Starzel 
started liver transplantation in 196314, it was 
suggested as a treatment for bleeding 
esophageal varices in 198815. During the 
period of the seventies and early 80s a great 
leap had occurred in the endoscopic treatment 
of varices. Thanks to Hopkins and Kapany16 
who in 1954 introduced the flexible 
fiberscope which was utilized by Hirschowitz 
for gastroscopy and demonstrated its use in 
195717. In 1961 Hirschowitz published his use 
of the new fiberscope18 for 
gastroduodenoscopy. This important progress 
in endoscopy has lead to its efficient use in 
flexible endoscopic sclerotherapy and 
banding of the gastro-oesophageal varices in 
the 1970s and onwards 19. It will prove later to 
be the greatest shareholder of the treatment of 
bleeding in portal hypertension20.  
    The unsatisfactory results of (DSRS) in 
patients with deteriorated liver function lead 
the radiologists to introduce in the 1990s a 
non-surgical shunt, Transjugular Intrahepatic 
Porto-systemic Shunt (TIPS) - as a salvage 
procedure for this category of patients. This 
procedure proved to be a strong competitor of 
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(DSRS) 21.    
    The foregoing summary showed the ever-
decreasing share of surgery in the treatment of 
bleeding in portal hypertension. Does it still 
hold a place in the armamentarium? 
Analysis of the present status: 
    Management of portal hypertension with 
varices is done in the following steps: 
  1- Prevention of the first bleed. The primary 
prophylaxis. 
  2- Treatment of active bleeding. 
  3- Prevention of recurrence of bleeding. The 
secondary prohylaxis. 
  4- Treatment of the underlying cause. 
    In this review, the share of different 
treatment modalities and the place of surgery 
in the first two steps will be determined by 
analyzing the available evidence. 
1- Prevention of the first bleed (primary 
prophylaxis). 
  Ten papers were identified that deal with 
primary surgical prophylaxis9,10,22-29. The first 
four were early papers written before the 
availability of the non-surgical primary 
prophylactic options. The fifth and ninth 
include meta-analysis of these papers24,28. The 
Japanese randomized a trial evaluating 
primary surgical prophylaxis 25 and the other 
three papers are qualitative reviews. 
    Surgery for portal hypertension was 
introduced to solve the problem of bleeding 
after the occurrence of the first bleed. When 
the results of the total shunt operations were 
published9,10,22,23, use of surgery for primary 
prophylaxis appeared to be inappropriate27-29. 
After the Warren shunt was introduced in 
196711 it proved to be a better alternative. A 
new hope to use the new operation for 
primary prophylaxis was revived. In 1980 the 
Japanese Research Society for Portal 
Hypertension started a prospective 
randomized controlled trial to evaluate 
primary surgical prophylaxis. They evaluated 
selective shunts and no shunting interruption 
procedures in patients who had portal 
hypertension but did not bleed. They reported 
their results in 199025. They concluded that 
"portal nondecompression surgery was 
effective in preventing the variceal bleeding 
and in improving survival". They did not 
compare their results of surgery to non-
surgical options for primary prophylaxis. 
Their control group received none of the 
newer treatments which became available at 
that time. Non-surgical primary prophylaxis 
became available during the 1980s with the 
introduction of flexible endoscopic 
sclerotherapy and banding, the β-blockade 
was added later in the decade. When the 
results of surgery were compared to these 
treatment modalities a general agreement 
between different researchers was that surgery 
should not be done for primary 
prophylaxis24,26-29. It is important to note that 
all these reviews use the same early studies of 
portacaval shunts9,10,22,23. No randomized 
controlled trials evaluating selective shunts 
and devascularization procedures could be 
found on the Internet except the Japanese 
study25.     
    Although some advocate the use of beta-
blockers for primary prophylaxis24, 26, 28-31, 
there is still no consensus about this24,32,. 
Other researchers claim that band ligation is 
superior to beta-blockers32,33 while a third 
group found the results to be equal34,35. The 
common rule is that when there is a contra-
indication to beta-blockers or the 
development of side-effects, band ligation 
should be substituted. Injection sclerotherapy 
for primary prophylaxis was not found to be 
of benifit28,31,36,37. 
    No surgery for primary prophylaxix: level 
of  evidence is 1. 
  2- Emergency treatment of active bleeding.    
   Baloon tamponade was the only other 
practical alternative beside surgery to control 
the acute episode of bleeding from the varices 
up to 19505. During the 1950s vasopressin 
was introduced as a medical means of 
decreasing the portal blood pressure to control 
the bleeding. Both these modes of treatments 
were temporary measures that buy time to 
improve the condition of the patient for 
surgery which was the only definitive 
treatment. During the 1970s and 80s 
sclerotherapy became more effective and 
variceal banding was introduced. Their 
availability, relative ease and success in 
controlling the active bleeding in more than 
80% of the cases5 make urgent surgery rarely 
indicated. In those cases where control of 
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bleeding is not possible, resort to surgery is 
still needed. These patients are usually those 
with bad liver function, Childs-Pough class C 
and/or those complicated by other co-
morbidities who deteriorate more by the 
repeated, unsuccessful, non-surgical attempts 
at control. The surgical mortality, in these 
patients, is exceeding 80%5.  
   In the 1990s radiologists introduced TIPS to 
rescue the failures of non surgical treatments 
specially those with bad liver functions. This 
again pushed surgery further back. Taking 
into account all the available treatment 
modalities the question now is this: is there 
any evidence-based reason for urgent surgery 
to control bleeding in portal hypertension? To 
answer this question each of the treatment 
modalities will be considered to see if surgery 
is still needed.    
   Pharmacological control of active bleeding: 
    Drugs that lead to decrease in portal 
pressure should be administered to every 
patient as soon as possible38. Some advocate 
their pre-hospital use by the emergency team 
while driving the patient to hospital39. Its use 
had been proved to decrease the duration of 
hypotension and the need for blood 
transfusion40.  Even if the bleeding stops 
spontaneously, it is advisable to give these 
drugs. If the bleeding is active, balloon 
tamponade is applied as an addition to drugs 
while awaiting emergency endoscopic 
therapy. It is estimated that bleeding will 
recur in 40-60% of the patients treated in this 
way after an initial control 41and the mortality 
from the recurrence of bleeding approaches 
90% in patients of Child's-Pough grade C42. 
There is no means available to identify these 
patients who will rebleed. For this reason 
endoscopic sclerotherapy or band ligation has 
to be done for every patient as soon as 
possible during the same hospital admission 
even if the bleeding is controlled by these 
measures 41. As will be seen later, endoscopic 
treatment will control bleeding in up to 90-
95% of the cases which give it an advantage 
of more than 30% over drugs for acute 
bleeding.  
   Endoscopic treatment:    
     Urgent endoscopy has to be done for every 
patient presenting with upper GIT bleeding to 
know the source of bleeding and to treat it if 
possible. Endoscopic control of active 
bleeding varices was evaluated by several 
researchers.   
   Emergency endoscopic sclerotherapy: 
     In mid 1980s researchers from South 
Africa reported the results of a study43 that 
should have limited the liberal use of 
sclerotherapy which used to be repeated 
several times during the same hospital 
admission in an attempt to avoid surgery. 
They reported that up to two injection 
sessions of sclerotherapy for the same 
bleeding episode will give definitive control 
of bleeding in up to 86% of cases with a 
mortality of 21%. More than two injection 
sessions will increase the mortality up to 89% 
in poor risk patients. They concluded that if 
control of bleeding could not be achieved by 
two sclerotherapy sessions a third should not 
be attempted and another mode of treatment 
should be done. At that time only surgical 
intervention was available. In 1990 one of the 
above authors published a review44 in which 
he found that 90-95% of cases could be 
controlled by sclerotherapy and that surgery is 
needed only for the remaining 5-10%. Again 
in 1992 authors from the same institute 
published a review in which they define 
sclerotherapy failure as: further variceal bleed 
after two emergency injection treatments 
during a single hospital admission. They stick 
to the previous advise41 of no more than two 
endoscopic attempts to control bleeding. It is 
strange that they did not mention TIPS 
although it was widely known at that time. 
Another important finding was reached by 
Shemesh and colleques45 that early 
sclerotherapy, within six hours of 
presentation, is more effective and lead to less 
mortality and a higher control rate. These four 
papers are chosen in the beginning because 
they contain what makes the basic advice: 
1- Sclerotherapy should be done earlier rather 
than late to give the best result. 
2- Sclerotherapy should not be attempted 
more than twice for the same episode because 
that will lead to high mortality. 
3- Sclerotherapy will fail to control bleeding 
in 5-10% of cases that will need more 
invasive procedures. 
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   All or some of these conclusions will be 
repeated in various other researches28,38. 
However in a meta-analysis46 of randomized 
controlled trials comparing sclerotherapy to 
various drugs, no convincing evidence was 
found to support the use of emergency 
sclerotherapy for variceal bleeding in 
cirrhosis as the first, single treatment when 
compared with vasoactive drugs. This result 
stood in sharp contrast to the result of an 
earlier randomized controlled study47 which 
concluded that “Sclerotherapy carried out as 
the first treatment of the active variceal 
hemorrhage proved both safe and effective, 
even in the presence of major hemorrhage, 
and as compared to combined vasopressin and 
nitroglycerin it proved superior". Terblanche 
published a review in 1989 in which he 
recommended emergency sclerotherapy for 
acute bleeding 27. This controversy has lead to 
the idea of combining both therapies to get 
better results. A meta-analysis of randomized 
controlled trials48 comparing endoscopic 
control of bleeding alone versus endoscopic 
control combined with pharmacological 
means found the combination to be better in 
initial arrest of bleeding and five day 
hemostasis, but not in mortality. Another 
meta-analysis28 of trials that compare 
endoscopic sclerotherapy to surgery in the 
control of bleeding refractory to medical 
treatment showed surgery to be better in 
control of bleeding but the mortality was the 
same. Inspite of these results surgery is not 
considered as first line management tool for 
the following reasons: 
   1- Endoscopy is usually needed for the 
diagnosis of the cause of bleeding and its 
control can start here. 
   2- Sclerotherapy is easier to learn compared 
to portal hypertension surgery.  
   3- Physicians are actively involved in the 
management of portal hypertension and they 
will take a larger share when sclerotherapy is 
considered for control of bleeding before 
surgery. 
   But the last of the three basic points of 
advice above, sclerotherapy will fail to 
control bleeding in 5-10% of cases, should 
always be remembered and the surgeon has to 
be involved earlier before the patient 
deteriorates and mortality from surgery 
becomes prohibitively high. 
Emergency endoscopic band ligation: 
 Band ligation was introduced in 1986 and it 
rapidly became strong competitor to 
sclerotherapy. Four review articles49-52 
extracting conclusions from randomized 
controlled trials found that band ligation to be 
superior to sclerotherapy. However, the latter 
is still holding place when band ligation is not 
available. Combination of scleroterapy or 
band ligation with drugs is a logical 
alternative which was found more effective48.    
   All the above non-surgical methods, 
performed in the best centers, by the most 
experienced doctors will have up to 10% of 
the cases unresponsive to them. The 
descriptions of these 10% of patients who will 
continue to bleed inspite of all these measures 
have yet to be determined. Therefore early 
decision for alternative treatment gives better 
results than late when the patient becomes in 
a bad shape. 
   Summary of some of the above studies is 
shown in table 1. 
 
Gastropathy & gastric varices 
 
   Portal hypertension causes gastropathy 
and/or gastric varices. Prevention of bleeding 
from gastropathy is mainly done through 
pharmacological means. Endoscopic or 
surgical primary prevention of gastric varices 
are less well studied than oesophageal varices. 
Generally both procedures are not 
recommended in primary prevention. 
   Treatment of active bleeding from 
gastropathy cannot be controlled by 
endoscopic means or ballon tamponade. 
Pharmacotherapy can decrease the severity of 
bleeding but the only definitive treatment is 
surgery orTIPS53. Shunt surgery or 
oesophagectomy with total gastrectomy 
controls bleeding but has a high mortality.  
   For gastric varices all options are available: 
   Endoscopic treatment:  
Two studies assessed the use of 5% 
ethanolamine oleate. In the first54 control of 
bleeding was achieved in 93% of patients. Re-
bleeding rate was 13%  
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Table1: Sclerotherapy compared to other reatments for 




Auther                                  Year                                              Re-bleeding (OR  95% CI)          Mortality (OR  95% CI)  
 Westby 46                             1989 (RCT)* 
        Scl/vas+nitro*                                                                      0.91(0.32-2.63)                         0.59 (0.21-.70)          
D'Amico29                            1995   (metaanalysis)                                                                                                                                           
      scl/vas*                                                                                  0.66 (0.44-1.00)**                    0.97 (0.56-1.65)**                                                                                         
      scl/somatostatin*                                                                   0.43 (0.14-1.30)**                    0.97 (0.56-1.65)**    
Laine48                                  1995   (metaanalysis)                           
                     lig/scl*                                                                    0.52 (0.37- 0.74])                       0.67(0.46 - 0.98)    
Note: 
OR= odd ratio 
* RCT = Randomized Controled Trial, scl = sclerotherapy, vas= vasopressin, nitro= nitroglycerin, lig = band ligation,     
** pooled odds ratio 
 
and comulative mortality after one year was 
31%. In the second study55 the results were 
given for lesser curve and fundal varices 
separately. Control of bleeding was achieved 
in 54%, 26% and mortality was 7.7%, 41% 
respectively. In one study56 n-butyl-2-
cyanoacrylate was used for gastric varices. 
Acute bleeding was controlled in all cases. 
Rebleeding occurred in 10.3% and 
complications related to the procedure 
occurred in 6.9%. The varices were eradicated 
in 93.1% of the cases, 69% after only one 
session.   
   In one study57 5% ethanolamine oleate was 
compared to butyl cyanoacrylate. Control of 
bleeding was 67%, 93%, rebleeding was 30%, 
25% and mortality was 67%, 38% 
respectively. Although the results of these 
three parameters were better for butyl 
cyanoacrylate, complications were higher 
(41%, 46%).  
Surgery: 
   Two studies assessed emergency surgery for 
gastric varices. Mortality was 50% in the first 
study58. In the living ones varices recurred in 
all those who were treated with under-running 
of the bleeders alone but in none when 
ligation of the left gastric vein was added. In 
the second study DSRS was performed59. 
Mortality was 6.7%. No rebleeding occurred 
for two years.  
TIPS: 
   In one study TIPS was used60 to control 
bleeding from gastric varices. Initial 
haemostasis was achieved in all of them. 
Hospital mortality was 25% and early 
rebleeding was 16.7%. In another study61 
haemostasis was achieved in 90%, early 
rebleeding was 14% and hospital mortality 
was 25%.  
  In a study comparing the use of TIPS for 
gastric and oesophageal varices62 rebleeding 
rate was 20% and 14.7%, one year cumulative 
mortality was 30.7% and 38.7% respectively.   
Looking at table (2) the results are diverse 
and inconsistent. This is probably due to the 
extreme heterogeneity of the studies. Added 
to this is the small number of cases in each 
study which does not give enough power to 
make a sound conclusion. The studies in 
which surgery was done gave 100% initial 
haemostsis and zero percent rebleeding, but 
mortality is the highest if the odd result of 
ethanolamine of 67% mortality is excluded. 
TIPS gave high control of bleeding but also 
high mortality and rebleeding rates. A 
combined result for butyl cyanoacrylate and 
ethanolamine oleate gives for initial control 
96.5%, 64.5%, for mortality 22.4%, 39.2% 
and for rebleeding 17.2%, 20.4% respectively. 
This gives a better result for butyl 
cyanoacrylate. 
    A reasonable plan for the control of gastric 
variceal bleeding is to give pharmacotherapy 
and use balloon tamponade to buy time for 
endoscopic control with butyl cyanoacrylate. 
If this fails, then TIPS, if TIPS is not available 
or fails, then surgery. Selection of surgery 
depends on local experience.  
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Table (2) Control of bleeding from gastric varices. 
 












Gimson54 (EA) 1991 46    
                                 Lesser curve     13 54 7.7 --- 
                                     Fundal  22 26 41 --- 
Dhiman55 (BC) 2002 29 100 7.0 10.3 
Oho56                   1995     
                                   (EA)  24 67 67 30 
                                   (BC)  29 93 38 25 
Greig57 (under-running of bleeder 
     +or – left gastric vein ligation) 
1990 06 100 50 00 
Thomas58  (distal splenorenal 
shunt) 
1994 30 100 6.7 00 
Kuradusenge59    (TIPS)  1993 12 100 25 16.7 
Karl60                          (TIPS) 2003 32 90 25 14 
Tripathi61                 (TIPS) 2002 40 00 30.7 
years 
20 
EA=Ethanol amine, BC= butyl cyanoacrylate 
 
Emergency Surgery Or TIPS: 
A group of researchers summarized 63 their 
fifty years of experience in portal 
hypertension emergency surgery in the year 
2000 by the following: 
   "At the beginning, many emergency 
procedures (selective shunts, low-diameter 
shunts, and devascularizations) were done, 
with a high mortality rate. 
In the 1980s, the mortality was close to 40%. 
Thus, in the past 10 years, virtually no more 
emergency procedures have been performed". 
They treat patients with bad livers by non-
surgical means and if these fail they use TIPS. 
On the other extreme, Orloff and colleques 
advocate emergency surgery for all patients64. 
They produced the unparalleled results of less 
than 20% operative mortality and survival 
rates of 67% and 57% for 5 and 10 years 
respectively for consecutive, non-selected 
patients.      
   As the ancient Romans say "the best 
solution is the middle", so let us see if a 
middle could be found between these two 
extremes.  
   Only one meta-analysis is found which was 
published in 199528. It discussed the results of 
early experiences with TIPS till 1992. The 
author concluded that in cases refractory to 
non-surgical measures an emergency 
portacaval shunt or TIPS should be done, the 
latter being the best in patients with poor liver 
function, who shall further be considered for 
liver transplantation. A study evaluating the 
use of TIPS in controlling bleeding in portal 
hypertension was published in 199465 and was 
not included in the previous meta-analysis. It 
included 100 patients, 10 were treated on an 
emergency basis. Three of these ten patients 
died within 30 days making a hospital 
mortality of 33.3% from those treated 
urgently. Thirty–three percent had shunt 
stenosis or occlusion and 11% had rebleeding. 
These numbers were from the total and those 
from the ones treated on emergency basis 
were not given separately. Another study, also 
published in 1994 and not included in the 
meta-analysis, in which 20 patients were 
treated with TIPS, on an emergency basis, 
when non-surgical methods failed66. Twelve 
of them died of hepatic failure and sepsis 
within 40 days, making a mortality of 60%. 
Thirty percent had rebleeding within five 
days. Another two had late rebleeding due to 
occlusion of TIPS and ultimately a portacaval 
shunt was done for them.  
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   In 1996 Sanyal6 and collogues published a 
study of using TIPS semi-urgently in patients 
unresponding to non-surgical treatment with 
advanced age, sepsis, renal or pulmonary 
compromise, or other comorbid diseases. 
These patients were assessed and found 
unsuitable for portacaval shunt. Their 35-day 
mortality rate was 40%, early rebleeding of 
less than 7%. These patients, due to their 
sever conditions, were destined not to live for 
long. Six month later only 46% of them were 
alive.  
   Three studies comparing urgent TIPS to 
urgent surgery were retrieved. One 
randomized trial67 compared small-diameter 
prosthetic H-graft portacaval shunts to TIPS. 
They had total failure for TIPS to be 57% and 
for H-graft to be 26 %. The authors concluded 
that "TIPS resulted in more deaths, more 
rebleeding, and more than twice the treatment 
failures". They vote against TIPS. The same 
authors in a continuation of the same study 
published in 200168 wrote “Despite vigilance 
in monitoring shunt patency, TIPS provides 
less optimal outcomes than H-graft portacaval 
shunt for patients with portal hypertension 
and variceal bleeding".  
   The other was a non-randomized study69 
which compared TIPS with oesophageal 
transaction that were done on an urgent basis. 
Seven of the 18 patients planned for 
transaction were found unfit. The 30-day 
mortality in this group was 79%, and the 
rebleeding was 26.2%. In the TIPS group the 
30-day mortality was 42% and the rebleeding 
was 15.6%. In only two patients of the TIPS 
the shunt could not be placed. Jalan and 
colleques reviewed the evidence-based place 
of TIPS in the 1990s70 and recommended that 
TIPS should be used as a salvage procedure 
after failure of two endoscopic sessions. They 
did not bring the issue of the Childs-Pough 
class into the making of this decision. 
Although Rikkers71  and collogues did not 
consider Childs-Pough class C as a contra-
indication to emergency surgery, they 
consider TIPS more appropriate as these 
patients will die from hepatic failure before 
TIPS occlusion develops if liver 
transplantation is not done. They 
recommended selective shunt surgery for 
class A and B for its long term advantage over 
TIPS. Their operative mortality rate after 
emergency non-selective shunt was 41%. 
Childs-Pough class C made 64% of their 22 
patients. In distal-splenorenal shunt their 
operative mortality was 10% in twenty 
patients in whom 35% were class C. Modified 
Sugiura procedure was done for nine 
unshuntable patients with a hospital mortality 
of 33% and rebleeding in two patients 
(22.2%).  
   Emergency oesophageal transaction was 
evaluated in two studies. In one of them 
transaction was done for 30 patients72. The 
30-day mortality for class A was 0%, for class 
B was 16.7% and in class C was 81.8% and 
the overall mortality was 63%. 21 of the 22 
patients with class C died within one year. 
They concluded that oesophageal transection 
is effective at stopping variceal bleeding but 
does not modify the underlying disease; 
therefore such patients may benefit more from 
an intrahepatic portasystemic stent shunt 
while awaiting liver transplantation. In the 
other study73 operative mortality was nil for 
patients with extrahepatic obstruction and 
normal liver function, and was 53% for 
patients with cirrhosis.  
   Modefied Hassab operation was assessed in 
one study74 in which oesophageal transaction 
was not done. They reported a zero operative 
mortality and 23% rebleeding rate. In this 
study gastric varices disappeared in all 
patients and oesophageal varices in 62% of 
them.   
   The most recent study that is retrieved was 
published in February 200775. It evaluated the 
emergency shunt and devascularization 
procedures undertaken when non-surgical 
methods fail to control bleeding. Mortality 
and rebleeding being the main outcome 
measures 82 patients were included in the 
study. The hospital mortality among cirrhotics 
was 22% and non-cirrhotics 8%. In cirrhotic 
patients the mortality in class A was 11%, B 
was 20% and C was 31%. Mortality after 
devascularization was 20% and after shunt 
surgery was 6%. Primary failure to control 
bleeding occurred in three patients of 
devascularization (6%) and one patient in the 
shunted group (3%).  
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   The last four papers 5, 38, 42, 76 retrieved were 
qualitative reviews that were published along 
the way since the introduction of TIPS. They 
discussed papers that were published 
comparing TIPS and surgery. All of them 
reached a conclusion that the use of TIPS is 
preferred in emergency situations especially 
in patients with poor liver function, except 
Michael Henderson5 and collogues who were 
still asking for more evidence for the jury to 
decide. Their publication was the most recent 
one among the four. Summary of the above 
studies is given in tables (3) and (4). 
 
Table3:Mortality and rebleeding after emergency 
surgery. 
Auther Year No OM RB 
Orloff63    1994 43 19  NA 
Rikkers71 1994 51 27.5 NA 
Jalan69 1995 19 79 26.6 
Wu YK74 2002 15 00 23 
Willson72 2005 30 63 33 
Sharma75 2007 82 15 21 




Table4: Mortality and rebleeding after emergency 
TIPS. 
Auther Year No OM RB 
McCormick65 1994 20 20 30 
Rossle64 1994 10 33 NA 
Jalan69 1995 19 42 15.6 
Sanyal6 1996 30 40 6.7 
Total   34 15.9 
OM=Operative mortality 
RB= Re-bleeding 
For practical and ethical reasons 
randomization and control in such situation is 
not possible. What makes interpretation and 
comparison of these studies even more 
difficult is the following: 
1- Time from the start of the bleeding to 
surgery or TIPS application was not 
uniform.       
2- Whether the patient had received two or 
more endoscopy trials sometimes was not 
mentioned.       
   3- Childs-Pough class distribution in some 
studies was not mentioned. Even when 
mentioned the results of each class was 
sometimes not given separately, especially for 
class C.   
   4- Mortality was given after various 
periods: thirty-five days, forty days, six 
weeks, and some stick to the known 30-day 
hospital mortality. I wonder why such an 
easy, useful agreement is not adhered to! 
   The presence of a protocol for receiving and 
managing such patients is very important. It 
shortens the time-to-act which is very 
important when large volumes of blood are 
being lost. It is taken for granted that the 
place in which these studies were carried is 
well equipped, has plenty of resources and 
enthusiastic staff, but is it everywhere! 
   The combined operative mortality of all 
studies, tables (3) and (4), shows that the 
results of emergency surgery are better than 
TIPS (28.33/34). The rebleeding rate when 
combined is better in TIPS (24.65/15.9). The 
general comment that is repeated by most 
authors is this:       
   Patients with poor liver function, Childs-
Pough class C, or those with co-morbid 
conditions like renal failure, severe sepsis, 
uncontrollable ascitis or aspiration, who fail 
to respond to non-surgical means, should have 
TIPS for the following reasons: 
- TIPS is done without general anesthesia in 
almost all patients. 
- TIPS hospital mortality for Childs-Pough 
class C is lower than most surgeries. 
- The patients have short life expectancy and 
will die anyway of liver failure if liver 
transplantation is not done soon.    
   Surgery is preferred in patients with good 
liver function that are expected to live longer. 
Probably the reason to prefer surgery is the 
long-term problems of TIPS. It needs repeated 
checks and dilatation for occlusion. Unless 
new forms of stents are found, that are 
resistant to occlusion, surgery will continue to 
be the best bet. Selective shunts are the 
preferred type of surgery as explained by 
Livingstone and collogues"12 Avoiding TIPS 
or other complete shunts in patients with 
stable disease must be stressed because 
complete shunts will result in hepatocellular 
failure over a period of a few years, 
eventuating in a liver transplantation or the 
patient's death" 
   The problem of cost in the long term is also 
against TIPS. In a study comparing the cost of 
TIPS and surgery77the authors concluded that 
"The routine ultrasound follow-up of TIPS 
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and the incidence of dysfunction are the key 
elements that make TIPS a more expensive 
option in patients with long survival, such as 
Child’s class A cirrhosis patients".  
   The middle point between the two extremes 
of all-surgery and no-surgery could be: 
   a) Surgery for Childs-Pough class A and B. 
The type of surgery depends on the local 
experience. 
        Level of evidence is 3.   
   b) TIPS for Childs-Pough class C and those 
from class A and B with severe co-morbid 
conditions.            Level of evidence is 2.   
   Elmasry78 concluded that portal 
hypertension is a multidisciplinary problem in 
which portal non-decompressive surgery 
forms one arm. Other arms are 
pharmacotherapy, endoscopic therapy, TIPS 
and liver transplantation.    
   "Surgery or TIPS?" cries the Patient. That is 
the Question! 
   But, choice is not the only problem. TIPS is 
not available everywhere and the breed of 
experienced surgeons is on the brink of 
extinction. Michael Henderson exclaimed 
during the discussion of the paper presented 
to the American Southern Surgical 
Association by Livingstone and collogues78 in 
2006" Who is going to do the shunts? Are 
there any shunters still out there?"          
 
Fig(1) Algorithm of the primary prevention and 
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